Clinical Trial Update: SafeBoosC III Two-year Follow-up

View source ↗

Summary

Two-year neurodevelopmental follow-up results from the SafeBoosC III trial in extremely preterm infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Brain Injury
• Premature Birth Complications

Snippet

Sponsor: Gorm Greisen | Conditions: Deficits, Neurologic, Extreme Prematurity | Status: COMPLETED